The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) awarded three grants to investigators

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

PEREGRINE PHARMACEUTICAL, INC. said that the National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) awarded three grants to investigators to support research of bavituximab in combination with other therapeutics for the treatment of glioblastoma, head and neck cancer, and hepatocellular carcinoma. Funding for the three investigator-initiated clinical studies will take place through a $2...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login